Loading clinical trials...
Loading clinical trials...
A Phase I/II Study of Continuous, Concomitant Oral Treatment With BIBF 1120 and Pemetrexed - a Phase I, Open-label, Dose-escalation Study & a Phase II, 2 Arm, Randomized, Double-blind, Placebo-controlled Study in Japanese Patients With Stage IIIB/IV or Recurrent Non-small-cell Lung Cancer After Failure of Chemotherapy
Conditions
Interventions
BIBF 1120 M + Pemetrexed
BIBF 1120 H + Pemetrexed
+3 more
Locations
3
Japan
1199.28.003 Boehringer Ingelheim Investigational Site
Chiba,Kashiwa, Japan
1199.28.002 Boehringer Ingelheim Investigational Site
Miyakojima-ku, Osaka, Japan
1199.28.001 Boehringer Ingelheim Investigational Site
Osaka-Sayama, Osaka, Japan
Start Date
October 16, 2009
Primary Completion Date
February 16, 2015
Completion Date
February 16, 2015
Last Updated
March 6, 2025
NCT06667908
NCT04165798
NCT06875310
NCT07046923
NCT07222566
NCT06667076
Lead Sponsor
Boehringer Ingelheim
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions